BrightFocus-Funded Research Shows Parkinson’s Drug Could be Repurposed to Save Sight of Millions
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.
In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, that are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson’s patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
“Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before,” says senior author Brian McKay of the University of Arizona.
The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its “wet” form, the most devastating form of the disease.
“This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that ‘big data’ is not a buzzword—it is a bold and innovative new approach to science,” said BrightFocus president and CEO Stacy Pagos Haller.
Read more: New Study: Leading Cause of Blindness Could Be Prevented or Delayed
The Latest on: L-DOPA
[google_news title=”” keyword=”L-DOPA” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: L-DOPA
- Bezisterim by BioVie for Alzheimer’s Disease: Likelihood of Approvalon May 16, 2024 at 7:06 pm
Bezisterim is under clinical development by BioVie and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase transition ...
- Therapy for Dyskinesias in Parkinson's Disease Patientson May 13, 2024 at 5:00 pm
Dyskinesia hampers the quality of life for most Parkinson's disease patients following several years of therapy. However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients ...
- Catechol Market To Reach USD 2.3 Billion By 2032 | DataHorizzon Researchon May 13, 2024 at 2:00 am
The catechol market size was valued at USD 1.7 Billion in 2023 and is expected to reach a market size of USD 2.3 Billion by 2032 at a CAGR of 3.5%.Fort Collins, Colorado (GLOBE NEWSWIRE) -- The rise ...
- Neuropathy in Parkinson’s Disease May Be Related to L-Dopa Exposureon May 12, 2024 at 5:00 pm
Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...
- Parkinson’s Disease Treatmenton December 20, 2023 at 11:29 am
Dopaminergic medications fall into four main categories, listed in declining order of dopamine potency. Levodopa, or L-dopa, is the most effective drug for minimizing PD symptoms and is the initial ...
- 12 Best Robin Williams Movies of All Timeon November 21, 2023 at 4:00 pm
Choosing the best Robin Williams movies is no easy task—the man made so many good ones. While his most iconic performances often saw him play inspiring mentors—most notably in Dead Poets ...
- Let's hope miraculous 'awakenings' of 40-year coma patients are permanenton August 8, 2021 at 11:59 am
In 1973, the neurologist Oliver Sacks published his remarkable book, Awakenings, which was a chronicle of his treatment of patients trapped in catatonia, often for decades, and who were awakened ...
- Psychiatric and Cognitive Disorders in Parkinson's Diseaseon April 2, 2021 at 2:20 am
Cools, Roshan Barker, Roger A Sahakian, Barbara J and Robbins, Trevor W 2003. l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease.
- DOPA claims his account's mouse sensitivity is buggedon February 19, 2021 at 1:28 am
DOPA and several other high profile korean streamers like 준밧드 and 즈려 have come out saying there's a bug right now with their mouse sensitivity. DOPA, being the savant that he is, has previously ...
- Reduction of L-DOPA-induced dyskinesia in animal models of Parkinson diseaseon April 7, 2019 at 9:43 am
Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...
via Bing News